- Companies
- Viome
Viome Valuation, Funding & Investors
Viome is valued at $339M as of October 2022.
Last Viome valuation
$339M
Series C · Oct 2022
Last Viome funding round
$25M
Series D · Sep 2024
Cumulative funding Viome raised
$278M
across 7 funding rounds
Key investors in Viome
Khosla Ventures
Bold Capital Partners
WestRiver Group
Better Health Group
Marc Benioff
Ezaki Glico Co
About Viome
Viome is a Bellevue-headquartered precision health company analyzing microbiome, mitochondrial, and cellular data through at-home test kits. Established in 2016, it provides personalized nutrition and lifestyle recommendations based on RNA sequencing of gut, oral, and cellular samples. The platform tracks biological age and health metrics for users seeking optimized wellness plans.
Founded
2016
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Product sales
Valuation
$339M (Oct 2022)
Viome Valuation
Viome is currently valued at $339M, based on its Series C in October 2022.
The $67M round was led by Bold Capital Partners, with participation from WestRiver Group, Ocgrow Ventures, Khosla Ventures, Ezaki Glico Co and Better Health Group.
Viome valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Oct 2022 | Series C | $339M |
Viome Funding History
Viome has raised a total of $278M across 7 funding rounds.
Viome's first fundraising round was a $15M Series A in July 2017. The most recent completed round was a $25M Series D in September 2024.
Viome funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2024 | Series D | WestRiver Group; Bold Capital Partners; Khosla Ventures; Marc Benioff | $25M | - | Viome Life Sciences, founded in 2016 by Naveen Jain, develops at-home microbiome testing kits analyzing saliva, stool, and blood samples to provide personalized dietary supplements, biotics, food recommendations, and health diagnostics like CancerDetect for oral and throat cancer, which has FDA breakthrough device designation with 90% sensitivity and 95% specificity. The company operates in the growing microbiome health market and has expanded into preventive healthcare with over 30 predictive AI models for early detection of cancers, autoimmune disorders, and metabolic conditions. In September 2024, Viome closed a $25 million internal Series D funding round from existing investors including Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and others, bringing total funding raised to approximately $200-301 million across prior rounds like an $86.5 million oversubscribed Series C in 2023 and earlier Series B and A rounds. The proceeds will ramp up the diagnostic division, expand microbiome health and personalized solutions, and support hiring Kal Raman, former Amazon SVP and Samsung chief digital officer, as COO to lead these efforts. Viome has pursued unique partnerships such as with Nordstrom and CVS for test kit distribution, appointed Paris Hilton as investor and ambassador, and maintains a handful of peer-reviewed studies amid some scientific skepticism regarding methodology in the microbiome sector. |
| Aug 2023 | Series C | Bold Capital Partners (lead); Khosla Ventures (lead); WestRiver Group; Eastward Capital Partners; WR Hambrecht | $87M | - | Viome Life Sciences, founded in 2016 by Naveen Jain, develops at-home microbiome testing kits using proprietary RNA sequencing technology combined with AI to analyze stool, saliva, and blood samples, providing personalized nutrition recommendations, supplements, probiotics, and health insights including a Full Body Intelligence Test and oral/throat cancer diagnostic. The company closed an oversubscribed $86.5 million Series C funding round on August 18, 2023, co-led by Bold Capital Partners and Khosla Ventures, with participation from Eastward Capital Partners, WestRiver Group, WR Hambrecht, and others, bringing total funding to $175 million. Funds support R&D for new tests like oral health solutions and retail expansion, highlighted by a distribution deal placing Gut Intelligence Tests in 200 CVS stores nationwide. Viome has served over 350,000 consumers across 106 countries, processing 600,000 samples to refine its algorithms, and offers subscription services like $199/month full body health solutions. The company remains unprofitable as stated by Jain. In the competitive gut microbiome testing market, projected to reach $12.5 billion by 2025, Viome differentiates with metatranscriptomics and AI-driven personalization amid a surge in venture interest, having attracted investors like Marc Benioff. Subsequent developments include a $25 million raise in 2024 and an acquisition in November 2023. |
| Oct 2022 | Series C | Bold Capital Partners (lead); WestRiver Group; Ocgrow Ventures; Khosla Ventures; Ezaki Glico Co; Better Health Group | $67M | $339M | Viome is a direct-to-consumer health startup specializing in microbiome analysis, offering at-home tests such as Full Body Intelligence Test, Gut Intelligence Test, and Oral Health Intelligence Test, along with personalized supplements and subscriptions based on microbial and human gene expression data licensed from Los Alamos National Lab. The company leverages AI to provide health insights, precision nutrition, and diagnostics like CancerDetect for oral and throat cancer. In a November 2021 pre-Series C convertible round, Viome raised USD 54 million led by Ocgrow Ventures, bringing total funding over USD 125 million at that time, involving investors like Bold Capital Partners, Khosla Ventures, Ocgrow Ventures, and WestRiver Group. A later Series D round in August 2024 raised USD 25.4 million at a USD 366.2 million valuation to expand diagnostics and international markets. Viome's business model generates revenue from one-time test sales and recurring subscriptions for custom-formulated products, emphasizing data-driven personalization for chronic disease prevention. The company positions itself in the growing microbiome diagnostics market, valued at US$126 million in 2022 and projected to reach US$300 million by 2028 at 15.5% CAGR, driven by chronic diseases and personalized medicine demand. Gut health direct-to-consumer segment sees 35% annual growth per estimates. Viome continues developing precision drugs and vaccines, partnering in initiatives like eXp World Holdings' SUCCESS Health for nutrition-focused wellness. |
| Nov 2021 | Series C | Ocgrow Ventures (lead); WestRiver Group; Bold Capital Partners; Khosla Ventures; Ezaki Glico Co; Better Health Group | $54M | - | Viome is a Seattle-area health tech startup founded in 2016 by Naveen Jain, specializing in at-home microbiome testing kits that analyze stool samples via RNA sequencing to provide AI-driven personalized recommendations for diet, supplements, and probiotics. The company offers consumer products including a $199/month subscription for made-to-order supplements and has served over 300,000 customers by late 2021, with plans to reach one million the following year. Viome also develops cancer diagnostics and expanded partnerships, such as with GlaxoSmithKline for research on cancers and autoimmune diseases, and later with Nordstrom and CVS for retail distribution. In November 2021, Viome raised $54 million in a pre-Series C convertible funding round led by new investor Ocgrow Ventures, with participation from existing backers including Khosla Ventures, WestRiver Group, Ezaki Glico, Bold Capital Partners, and Physician Partners. This round brought the company's total funding to over $125 million at the time. Ocgrow Ventures' founder Harish Consul joined as a board observer. The capital was intended to bolster cancer diagnostics development and support the consumer product division. CEO Naveen Jain stated in 2021 that Viome was on track for $100 million in revenue the following year. The company remained unprofitable as of later updates. Subsequent rounds included an additional $67 million Series C tranche in 2022 led by Bold Capital Partners, an $86.5 million Series C close in 2023, and a $25 million Series D in 2024 led by Khosla Ventures, Bold Capital WRG Ventures, and Marc Benioff, focusing on new diagnostic divisions and AI health solutions. |
| Apr 2019 | Series B | Marc Benioff (lead); Bold Capital Partners; Matthew Harris; Veronorte; Nomad Capital Partners; Hambrecht Healthcare Growth Venture Fund; Better Health Group | $25M | - | - |
| Jul 2018 | Series B | Better Health Group (lead); Khosla Ventures | $6M | - | Viome raised $5.5 million in a Series B funding round in July 2018 led by Better Health Group with participation from Khosla Ventures. The funds supported expansion of product offerings and enhancement of AI capabilities. This round followed a Series A of $15 million in July 2017 led by Khosla Ventures to develop and launch initial microbiome testing products. |
| Jul 2017 | Series A | Khosla Ventures (lead); Bold Capital Partners | $15M | - | Viome raised $15 million in its Series A funding round in July 2017, led by Khosla Ventures with participation from Bold Capital Partners, bringing total funding to $21 million. The capital supported the launch of its at-home health kit targeting the microbiome, with the company operating an early beta program with several thousand customers and planning wide availability in the US, UK, Canada, India, and the Middle East starting in September. Khosla Ventures received one board seat. Viome provides AI-powered wellness services offering insights into personal health through microbiome analysis. The company was co-founded by entrepreneur Naveen Jain and features experts like Chief Science Officer Momo Vuyisich from Los Alamos National Laboratory and Chief Medical Officer Helen Messier from Human Longevity, Inc. At the time, Viome had 45 employees across Los Alamos, New York, and Cupertino, California. Vinod Khosla described Viome as a transformational healthcare company focused on preventing illnesses using AI, health, and science expertise. |
Who has invested in Viome?
13 investors have backed Viome across its funding rounds, including Khosla Ventures, Bold Capital Partners, WestRiver Group, Better Health Group, Marc Benioff and Ezaki Glico Co.
Lead investors include Bold Capital Partners, Khosla Ventures, Ocgrow Ventures, Marc Benioff and Better Health Group.
Viome Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 6 | Lead | Jul 2017 | ||
| 6 | Lead | Jul 2017 | ||
| 4 | Participant | Nov 2021 | ||
| 4 | Lead | Jul 2018 | ||
| 2 | Lead | Nov 2021 | ||
| 2 | Participant | Nov 2021 | ||
| 2 | Lead | Apr 2019 | ||
| -- | 1 | Participant | Apr 2019 | |
| 1 | Participant | Apr 2019 | ||
| 1 | Participant | Apr 2019 | ||
| 1 | Participant | Apr 2019 | ||
This data is available for Pro users. Sign up to see all 13 Viome investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Viome
Viome has acquired 4 companies to date.
Last acquisition by Viome was on August 12th 2026. Viome acquired Circulate for undisclosed valuation.
Latest Acquisitions by Viome
| Description | Circulate is a San Francisco-based biotech firm developing therapeutics to extend healthy lifespan through science-based interventions. Its pipeline targets age-related diseases with small molecule drugs undergoing preclinical trials. Founded in 2023, Circulate focuses on mitochondrial function and cellular senescence markers. | DiscernDx is a Palo Alto-based health data platform aggregating clinical lab results, genomic profiles, and wearable metrics. Founded in 2017, it provides longitudinal health dashboards for early detection of chronic conditions like diabetes and cardiovascular disease through consumer subscriptions. | Naring Health is a digital platform specializing in health and wellness through customized access to clinical and molecular data. This service supports users in making precise, data-informed decisions about their health management. | Habit Food Personalized is an Oakland, California-headquartered personalized nutrition company founded in 2015. It supplies at-home kits for DNA analysis and blood biomarker testing, followed by custom meal deliveries, dietitian consultations, and a mobile app for goal tracking and community sharing. |
| HQ Country | ||||
| HQ City | Seattle, WA | San Francisco, CA | San Francisco, CA | San Francisco, CA |
| Deal Date | 12 Aug 2026 | 2 Nov 2023 | 2 Nov 2023 | 6 Feb 2019 |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Viome acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Viome Competitors
Viome competitors include listed companies like DarioHealth and Echo IQ, and private ones like Well, Biopeak, Glooko and Evidation Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $450M | - | ||
| Private | $2M | - | $250M | 125.0x | ||
| Private | - | - | $476M | - | ||
| Private | - | - | $1B | - | ||
| Publicly listed | $22M | ($36M) | $69M | 4.0x | ||
| Publicly listed | $65K | ($13M) | $311M | 994.2x |
Viome Public Comps
Viome is still privately-owned, but its public comps include Echo IQ, Cogstate, Evolent Health, TaiDoc Technology, Yidu Tech, Bayzed Health Group, Nyxoah, Ever Fortune.AI, Veradigm and OptimizeRx.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65K | ($13M) | 4656.6x | 994.2x | (23.1x) | (26.6x) | |||
| $58M | $18M | 6.3x | 5.7x | 20.0x | 18.9x | |||
| $1.9B | ($365M) | 0.7x | 0.5x | (3.5x) | 9.4x | |||
| $132M | $58M | 2.1x | - | 4.8x | - | |||
| $122M | ($4M) | 1.4x | 1.2x | (45.0x) | 7.7x | |||
| $167M | $18M | 3.0x | - | 28.4x | - | |||
| $12M | ($97M) | 9.5x | 3.2x | (1.1x) | (1.4x) | |||
| $12M | $4M | 12.3x | - | 36.2x | - | |||
This data is available for Pro users. Sign up to see all Viome competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Viome
| When was Viome founded? | Viome was founded in 2016. |
| Where is Viome headquartered? | Viome is headquartered in Seattle, WA, United States. |
| Is Viome publicly listed? | No, Viome is a private, VC-backed company. |
| What is Viome's valuation? | Viome was last valued at $339M in its Series C in October 2022. |
| How much funding has Viome raised? | Viome has raised $278M across 7 funding rounds. |
| What was Viome's last funding round? | Viome's last funding round was a $25M Series D in September 2024. |
| Who are Viome's investors? | Viome's investors include Bold Capital Partners, Khosla Ventures, WestRiver Group, Better Health Group, Ocgrow Ventures, Ezaki Glico Co, Marc Benioff, Matthew Harris, Veronorte, Nomad Capital Partners and 3 others. |
| Which companies are comparable to Viome? | Companies comparable to Viome include Well, Biopeak, Glooko, Evidation Health, DarioHealth and Echo IQ. |
| How many companies has Viome acquired? | Viome has acquired 4 companies, including Circulate, DiscernDx, Naring Health and Habit Food Personalized. |
See companies similar to Viome
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




